- Home
- ATPC vs MAIA Comparison
ATPC vs MAIA Comparison
Compare ATPC & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATPC
- MAIA
- Stock Information
- Founded
- ATPC 2016
- MAIA 2018
- Country
- ATPC Malaysia
- MAIA United States
- Employees
- ATPC N/A
- MAIA N/A
- Industry
- ATPC Medical/Nursing Services
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- ATPC Health Care
- MAIA Health Care
- Exchange
- ATPC Nasdaq
- MAIA Nasdaq
- Market Cap
- ATPC 68.0M
- MAIA 56.3M
- IPO Year
- ATPC N/A
- MAIA 2022
- Fundamental
- Price
- ATPC $1.31
- MAIA $1.70
- Analyst Decision
- ATPC
- MAIA
- Analyst Count
- ATPC 0
- MAIA 0
- Target Price
- ATPC N/A
- MAIA N/A
- AVG Volume (30 Days)
- ATPC 42.3K
- MAIA 465.7K
- Earning Date
- ATPC 08-13-2025
- MAIA 08-08-2025
- Dividend Yield
- ATPC N/A
- MAIA N/A
- EPS Growth
- ATPC N/A
- MAIA N/A
- EPS
- ATPC N/A
- MAIA N/A
- Revenue
- ATPC $1,293,141.00
- MAIA N/A
- Revenue This Year
- ATPC N/A
- MAIA N/A
- Revenue Next Year
- ATPC N/A
- MAIA N/A
- P/E Ratio
- ATPC N/A
- MAIA N/A
- Revenue Growth
- ATPC N/A
- MAIA N/A
- 52 Week Low
- ATPC $0.90
- MAIA $1.40
- 52 Week High
- ATPC $5.96
- MAIA $3.74
- Technical
- Relative Strength Index (RSI)
- ATPC 43.69
- MAIA 44.78
- Support Level
- ATPC $1.28
- MAIA $1.64
- Resistance Level
- ATPC $1.48
- MAIA $1.74
- Average True Range (ATR)
- ATPC 0.10
- MAIA 0.09
- MACD
- ATPC 0.01
- MAIA -0.01
- Stochastic Oscillator
- ATPC 21.06
- MAIA 11.76
About ATPC Agape ATP Corporation
Agape ATP Corp through its subsidiaries is engaged in providing health and wellness products and health solution advisory services. The principal activities of the company is to supply high-quality health and wellness products, including supplements to assist in cell metabolism, detoxification, blood circulation, anti-aging and products designed to improve the overall health system of the human body and various wellness programs. Its segments include: Skin care, health and wellness segment includes the provision of health and wellness products and health solution advisory services; and Green energy segment includes providing renewable energy products, technical solutions, installations and maintenance services. It derives maximum revenue from Skin care, health and wellness segment.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.